Skip to main content
. Author manuscript; available in PMC: 2023 Dec 26.
Published in final edited form as: Leukemia. 2022 Dec 22;37(3):560–570. doi: 10.1038/s41375-022-01798-5

Figure 6. CXCL12 KO enhances response to combination chemotherapy plus quizartinib.

Figure 6.

(A) WBC counts (left), %c-Kit+ cells (center), and %Gr-1 high mature neutrophils in PB (right), and (B) spleen weights (left), BM LSK (center) and BM ST-HSC (right) in CXCL12-WT or CXCL12-KO mice treated with vehicle control or combination chemotherapy plus quizartinib. (C) Kaplan-Meier survival analysis of secondary transplants of 2 x 10^6 BM MNC from control, KO-Veh, WT-Rx, or KO-Rx mice into WT recipient mice. Significance values: *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. Results represent mean ± SEM of multiple replicates.